August 1, 2024Open Access
View Full PaperThe Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering
Key Points
Key points are not available for this paper at this time.
Abstract
Olpasiran, a small interfering RNA (siRNA), blocks lipoprotein(a) (Lp(a)) production by preventing translation of apolipoprotein(a) mRNA. In phase 2, higher doses of olpasiran every 12 weeks (Q12W) reduced circulating Lp(a) by >95%.